Results 91 to 100 of about 291,785 (296)

Finding novel vulnerabilities of hypomorphic BRCA1 alleles

Molecular Oncology, EarlyView.
Synthetic lethality screens performed to identify novel vulnerabilities often model complete gene loss, thereby overlooking patient‐derived hypomorphic mutations. In this study, we have performed genome‐wide CRISPR screens on BRCA1 hypomorphic mutations, showing BRCA1I26A behaves like wild‐type, while BRCA1R1699Q mimics deficiency. Furthermore, we have
Anne Schreuder, Klaas de Lint, Hồ Mỹ Phúc Võ, Mariana M. Góis, Rosalie A. Kampen, Marta San Martin Alonso, Ilse Nootenboom, Veronica Garzero, Tiemen J. Wendel, Rob M. F. Wolthuis, Sylvie M. Noordermeer   +10 more
wiley   +1 more source

TLR9 activation cooperates with T cell checkpoint blockade to regress poorly immunogenic melanoma

Journal for ImmunoTherapy of Cancer, 2019
Tumors that lack pre-existing immune infiltration respond poorly to T cell checkpoint blockade immunotherapy. These cancers often surround themselves with high densities of suppressive myeloid stroma while excluding immunostimulatory dendritic cells ...
Matthew J. Reilley, Brittany Morrow, Casey R. Ager, Arthur Liu, David S. Hong, Michael A. Curran   +5 more
doaj   +1 more source

Hallmarks of response to immune checkpoint blockade [PDF]

British Journal of Cancer, 2017
Unprecedented advances have been made in the treatment of cancer through the use of immune checkpoint blockade, with approval of several checkpoint blockade regimens spanning multiple cancer types. However, responses to this form of therapy are not universal, and insights are clearly needed to identify optimal biomarkers of response and to combat ...
Cogdill, Alexandria P, Andrews, Miles C, Wargo, Jennifer A   +2 more
openaire   +2 more sources

MITF maintains genome stability in nonmelanocyte lineages

Molecular Oncology, EarlyView.
MITF is essential for melanocyte survival and acts as an oncogene in 10%–20% of melanomas. We show that MITF depletion causes genome instability in nonmelanocytic cells, leading to LATS2‐mediated P53 activation, cell cycle arrest, and apoptosis. This study highlights the role of MITF as a genome maintenance factor beyond the melanocyte lineage. Created
Drifa H. Gudmundsdottir, Adrián López García de Lomana, Thejus B. Venkatesh, Kritika Kirty, Snaevar Sigurdsson, Linda Vidarsdottir, Ramile Dilshat, Erla Sveinbjornsdottir, Snaedis Ragnarsdottir, Daniel H Magnusson, Maria R. Bustos, Eirikur Steingrimsson, Thorkell Gudjonsson, Stefan Sigurdsson   +13 more
wiley   +1 more source

Epigenetic heterogeneity and plasticity in therapy‐induced tumor states through single‐cell multi‐omics

Molecular Oncology, EarlyView.
Single‐cell multi‐omics reveals epigenetic heterogeneity across therapy‐adaptive tumor states, including quiescent/dormant, drug‐tolerant persister, and EMT‐like phenotypes. By linking regulatory features with state‐associated biomarkers, these approaches inform biomarker‐guided therapeutic strategies for evolving tumors.
Hee Jung Kim, Hwiyeong Lee, Jin Hong, Daechan Park   +3 more
wiley   +1 more source

Combination systemic therapies with immune checkpoint inhibitors in pancreatic cancer: overcoming resistance to single-agent checkpoint blockade

Clinical and Translational Medicine, 2018
Immune checkpoint inhibitors have demonstrated broad single-agent antitumor activity and a favorable safety profile that render them attractive agents to combine with other systemic anticancer therapies.
Jun Gong, Andrew Hendifar, Richard Tuli, Jeremy Chuang, May Cho, Vincent Chung, Daneng Li, Ravi Salgia   +7 more
doaj   +1 more source

LIGHTing tumor up for checkpoint blockade

Oncotarget, 2016
Immune checkpoint blockade, as a breakthrough in cancer therapy with anti-PD-L1, anti-PD-1, and anti- CTLA4, has demonstrated impressive therapeutic effects in multiple clinical trials. However, only a small minority of patients respond to such therapies [1]. Higher tumor infiltrating lymphocytes (TILs) and PD-L1 expression in tumors have been found to
Liang, Yong, Peng, Hua
openaire   +2 more sources

Cancer‐associated mutations in endometriosis reframe a benign disease through molecular oncology

Molecular Oncology, EarlyView.
This review aims to comprehensively analyse cancer‐associated somatic mutations (CAMs) present in endometriotic lesions, emphasizing their biological roles, spatial distribution and implications for translational applications in medicine. By contextualizing a benign state within a genomic framework, this analysis seeks to establish its value as a ...
Clarissa Mujacic, Maria Concetta Vitale, Rita Siino, Emilia Di Giovanni, Carla Ferrante Bannera, Enrico Di Marco, Andrea Gottardo, Tancredi Didier Bazan Russo, Nadia Barraco, Alessandro Perez, Valerio Gristina, Antonio Galvano, Giuseppe Badalamenti, Antonio Russo, Viviana Bazan, Lorena Incorvaia   +15 more
wiley   +1 more source

Predictive biomarkers for tumor immune checkpoint blockade

, 2018
Mengting Tong,1,2,* Jing Wang,2,* Wenting He,1 Yanling Wang,2 Hongming Pan,2 Da Li,2 Hongliang Zhang1 1Second Department of Medical Oncology, The Fourth Affiliated Hospital of Xinjiang Medical University, Saybagh District, Urumqi, Xinjiang 830000, People&
Pan H, Li D, He W, Tong M, Zhang H, Wang Y, Wang J   +6 more
core  

Investigation into how mitotic spindle checkpoint function is compromised by Sv40 large T antigen. [PDF]

, 2005
The viral oncoprotein Simian virus 40 large T antigen (LT) efficiently immortalises primary rodent cells and occasionally transforms them to tumourigenicity.
Lock, Rowena Lesley, Lock, R.L.
core